137 related articles for article (PubMed ID: 36740817)
1. Rhabdomyolysis during concomitant ticagrelor and rosuvastatin: A breast cancer resistance protein-mediated drug interaction?
Lehtisalo M; Kiander W; Filppula AM; Deng F; Kidron H; Korhonen M; Sinkko J; Koivula K; Niemi M
Br J Clin Pharmacol; 2023 Jul; 89(7):2309-2315. PubMed ID: 36740817
[TBL] [Abstract][Full Text] [Related]
2. Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Tarkiainen EK; Neuvonen M; Holmberg M; Kiiski JI; Lapatto-Reiniluoto O; Filppula AM; Kurkela M; Backman JT; Niemi M
Clin Pharmacol Ther; 2024 Jan; 115(1):71-79. PubMed ID: 37786998
[TBL] [Abstract][Full Text] [Related]
3. Calibrating the In Vitro-In Vivo Correlation for OATP-Mediated Drug-Drug Interactions with Rosuvastatin Using Static and PBPK Models.
Sane R; Cheung KWK; Kovács P; Farasyn T; Li R; Bui A; Musib L; Kis E; Plise E; Gáborik Z
Drug Metab Dispos; 2020 Dec; 48(12):1264-1270. PubMed ID: 33037044
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile.
Vrkić Kirhmajer M; Macolić Šarinić V; Šimičević L; Ladić I; Putarek K; Banfić L; Božina N
Basic Clin Pharmacol Toxicol; 2018 Oct; 123(4):509-518. PubMed ID: 29734517
[TBL] [Abstract][Full Text] [Related]
6. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
9. P-Glycoprotein and Organic Anion Transporter Polypeptide 1B/Breast Cancer Resistance Protein Drug Transporter Activity in Pregnant Women Living With HIV.
Moreira FL; Melli PPDS; Marques MP; Rocha A; Nardotto GHB; Duarte G; Lanchote VL
J Clin Pharmacol; 2023 Feb; 63(2):219-227. PubMed ID: 36087110
[TBL] [Abstract][Full Text] [Related]
10. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
Costales C; Lin J; Kimoto E; Yamazaki S; Gosset JR; Rodrigues AD; Lazzaro S; West MA; West M; Varma MVS
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1018-1031. PubMed ID: 34164937
[TBL] [Abstract][Full Text] [Related]
11. Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin.
Wang Q; Zheng M; Leil T
CPT Pharmacometrics Syst Pharmacol; 2017 Apr; 6(4):228-238. PubMed ID: 28296193
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
[TBL] [Abstract][Full Text] [Related]
13. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
15. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3.
Heinig R; Fricke R; Wertz S; Nagelschmitz J; Loewen S
Eur J Drug Metab Pharmacokinet; 2022 Nov; 47(6):803-815. PubMed ID: 36029368
[TBL] [Abstract][Full Text] [Related]
16. Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Huh Y; Plotka A; Wei H; Kaplan J; Raha N; Towner J; Purohit VS; Dowty ME; Wolk R; Vourvahis M; King-Ahmad A; Mathialagan S; West MA; Lazzaro S; Ryu S; Rodrigues AD
Pharm Res; 2023 Nov; 40(11):2639-2651. PubMed ID: 37561322
[TBL] [Abstract][Full Text] [Related]
17. Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin.
Lehtisalo M; Keskitalo JE; Tornio A; Lapatto-Reiniluoto O; Deng F; Jaatinen T; Viinamäki J; Neuvonen M; Backman JT; Niemi M
Clin Transl Sci; 2020 Nov; 13(6):1236-1243. PubMed ID: 32453913
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Elsby R; Coghlan H; Edgerton J; Hodgson D; Outteridge S; Atkinson H
Pharmacol Res Perspect; 2023 Apr; 11(2):e01060. PubMed ID: 36811234
[TBL] [Abstract][Full Text] [Related]
19. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin.
Johnson M; Patel D; Matheny C; Ho M; Chen L; Ellens H
Drug Metab Dispos; 2017 Jan; 45(1):27-34. PubMed ID: 27737931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
